GENELUX Corp — Insider Transactions
Form 4 filings by directors, officers, and 10%+ shareholders
SEC rules require corporate insiders — including directors, executive officers, and any shareholder owning more than 10% of a company's shares — to report changes in their ownership within two business days of a transaction. These disclosures are filed as Form 4. Open-market purchases (code P) are generally considered the most meaningful signal, as insiders are spending their own money.
| Insider | Title | Type | Shares | Price | Value | Owns After | Date |
|---|---|---|---|---|---|---|---|
| Mirabelli Mary | — | Purchase | 8,000 | — | — | 12,460 | May 29, 2024 |
| Yu Yong | VP, Clinical Trial Operations | Purchase | 2,500 | — | — | 2,500 | May 29, 2024 |
| Zindrick Thomas | President and CEO | Purchase | 200,000 | — | — | 200,000 | May 29, 2024 |
| Smalling Ralph | Head of Regulatory | Purchase | 1,250 | — | — | 13,315 | May 29, 2024 |
| Ryder Sean | General Counsel | Purchase | 10,000 | — | — | 10,572 | May 29, 2024 |
| Zak Lourie S. | Chief Financial Officer | Purchase | 31,250 | — | — | 31,250 | May 29, 2024 |
| Szalay Aladar | — | Sale | 15,426 | $3.58 | $55,225 | 1,156,915 | May 13, 2024 |
| Szalay Aladar | — | Sale | 6,025 | $3.67 | $22,112 | 1,189,706 | May 8, 2024 |
| Szalay Aladar | — | Sale | 33,061 | $3.30 | $109,101 | 1,195,731 | Apr 30, 2024 |
| Szalay Aladar | — | Sale | 22,000 | $3.49 | $76,780 | 1,263,794 | Apr 22, 2024 |
| Szalay Aladar | — | Sale | 22,737 | $3.71 | $84,354 | 1,300,125 | Apr 16, 2024 |
| Zindrick Thomas | President and CEO | Award / Grant | 8,320 | — | — | 22,971 | Mar 14, 2024 |
| Zak Lourie S. | Chief Financial Officer | Award / Grant | 1,220 | — | — | 32,470 | Mar 14, 2024 |
| Smalling Ralph | Head of Regulatory | Award / Grant | 616 | — | — | 13,931 | Mar 14, 2024 |
| Cappello Joseph | VP, Pharmaceutical Development | Award / Grant | 3,661 | — | — | 9,396 | Mar 14, 2024 |
| Ryder Sean | General Counsel | Award / Grant | 2,936 | — | — | 13,508 | Mar 14, 2024 |
| Jewett Caroline | Head of Quality | Sale | 4,961 | $2.12 | $10,517 | 16,174 | Feb 19, 2024 |
| Yu Yong | VP, Clinical Trial Operations | Sale | 26,732 | $12.94 | $345,912 | 5,803 | Dec 15, 2023 |
| Tyree James L | — | Sale | 5,653 | $12.91 | $72,980 | 6,807 | Dec 13, 2023 |
| Thomas John | — | Sale | 7,073 | $13.23 | $93,576 | 465,387 | Dec 13, 2023 |
| Yu Yong | VP, Clinical Trial Operations | Sale | 36,800 | $11.85 | $436,080 | 32,535 | Dec 7, 2023 |
| Yu Yong | VP, Clinical Trial Operations | Sale | 18,665 | $10.26 | $191,503 | 69,335 | Nov 21, 2023 |
| Yu Yong | VP, Clinical Trial Operations | Sale | 3,541 | $13.04 | $46,175 | 102,594 | Nov 20, 2023 |
| Szalay Aladar | — | Sale | 5,704 | $19.40 | $110,658 | 1,371,545 | Oct 25, 2023 |
| Yu Yong | VP, Clinical Trial Operations | Option Exercise | 5,200 | $6.00 | $31,200 | 111,335 | Oct 24, 2023 |
| Szalay Aladar | — | Sale | 49,987 | $19.97 | $998,240 | 1,377,249 | Oct 23, 2023 |
| Thomas John | — | Sale | 2,452 | $20.50 | $50,266 | 473,341 | Oct 16, 2023 |
| Yu Yong | VP, Clinical Trial Operations | Sale | 4,800 | $21.94 | $105,312 | 106,535 | Oct 10, 2023 |
| Szalay Aladar | — | Sale | 13,266 | $24.89 | $330,191 | 1,428,221 | Oct 5, 2023 |
| Szalay Aladar | — | Sale | 75,690 | $25.49 | $1,929,338 | 1,441,487 | Oct 3, 2023 |
| Szalay Aladar | — | Sale | 2,289 | $24.12 | $55,211 | 1,517,177 | Sep 27, 2023 |
| Yu Yong | VP, Clinical Trial Operations | Option Exercise | 5,200 | $6.00 | $31,200 | 111,335 | Sep 26, 2023 |
| Szalay Aladar | — | Sale | 1,100 | $27.81 | $30,591 | 1,560,528 | Sep 25, 2023 |
| Szalay Aladar | — | Sale | 2,871 | $27.89 | $80,072 | 1,586,706 | Sep 22, 2023 |
| Yu Yong | VP, Clinical Trial Operations | Sale | 6,000 | $27.96 | $167,760 | 106,135 | Sep 20, 2023 |
| Ryder Sean | General Counsel | Option Exercise | 10,000 | $6.00 | $60,000 | 10,572 | Sep 20, 2023 |
| Szalay Aladar | — | Sale | 27,365 | $23.20 | $634,868 | 7,927 | Sep 18, 2023 |
| Thomas John | — | Sale | 1,088 | $22.38 | $24,349 | 479,127 | Sep 18, 2023 |
| Yu Yong | VP, Clinical Trial Operations | Sale | 5,725 | $21.56 | $123,431 | 110,810 | Sep 15, 2023 |
| Yu Yong | VP, Clinical Trial Operations | Sale | 29,800 | $21.14 | $629,972 | 106,135 | Sep 13, 2023 |
| Szalay Aladar | — | Sale | 13,871 | $22.31 | $309,462 | 35,292 | Sep 13, 2023 |
| Smither John W | — | Sale | 900 | $20.78 | $18,702 | 6,920 | Sep 13, 2023 |
| Mirabelli Mary | — | Award / Grant | 3,460 | — | — | 4,460 | Sep 11, 2023 |
| Tyree James L | — | Award / Grant | 3,460 | — | — | 12,460 | Sep 11, 2023 |
| Thomas John | — | Award / Grant | 3,460 | — | — | 482,460 | Sep 11, 2023 |
| Smither John W | — | Award / Grant | 6,920 | — | — | 7,820 | Sep 11, 2023 |
| Szalay Aladar | — | Sale | 9,331 | $21.39 | $199,590 | 122,885 | Sep 11, 2023 |
| Smalling Ralph | Head of Regulatory | Award / Grant | 10,000 | — | — | 12,065 | Sep 11, 2023 |
| Jewett Caroline | Head of Quality | Award / Grant | 20,000 | — | — | 21,135 | Sep 11, 2023 |
| Szalay Aladar | — | Sale | 8,523 | $23.49 | $200,205 | 134,852 | Sep 8, 2023 |